Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

DapaBalci-Leap Ended

2024-516032-10-00 Stage 3 chronic kidney disease 2023-07-13
Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma Ended

2024-518704-41-00 Mantle cell lymphoma 2023-07-12
A phase 2a study of CR9114 in healthy adult participants Ended

2023-505020-57-00 Influenza virus 2023-07-10
Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA) Ended

2024-516321-31-00 Type 3 spinal muscular atrophy 2023-07-07
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 2023-07-03
Treatment of Keratolytic Winter Erythema in adults with systemic nitroxoline Ended

2022-501726-38-00 Keratolytic Winter Erythema 2023-06-30
Basimglurant in children, adolescents, and young adults with TSC Ended

2024-512611-53-00 Tuberous Sclerosis Complex 2023-06-30
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended

2024-512646-42-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 2023-06-27
Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (Neo… Ended

2024-515660-31-00 intrahepatic cholangiocarcinoma 2023-06-27
Open-label study to assess safety and efficacy of rapamycin in drugresistant epilepsy associated with mTOR pathway pathologies Ended

2024-515950-25-00 epilepsy, mTORopathies, focal cortical dysplasia, LEATS 2023-06-27
A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended

2022-501470-18-00 Thromboembolic disease 2023-06-26
A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease Ended

2024-515177-94-00 Parkinson's Disease 2023-06-21
Glucagon enhanced insulin absorption in Diabetes Mellitus type 1 Ended

2022-502455-57-01 Diabetes mellitus type 1 2023-06-20
Evaluation of the Effects of Neurexan® on Short-Term Insomnia, Daytime Performance and Stress Response by Polysomnography (PSG), Electroence… Ended

2024-514391-41-00 Short-Term Insomnia 2023-06-16
A Phase 2, Single-Blind, Placebo-Controlled Trial to Evaluate the Photoparoxysmal Electroencephalogram Response, Safety, Tolerability, and P… Ended

2023-504803-10-00 IPS induced photoparoxysmal electroencephalogram respon 2023-06-15
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones. Ended

2024-512647-23-00 Grave's disease 2023-06-14
SEMALCO Ended

2023-503371-25-00 Alcohol Use Disorder 2023-06-08
Phase 2a, Random, double masked, Placebo-controlled, side by side group, multiple center study evaluating the effectiveness and safety of ST… Ended

2024-517104-11-00 Fuchs Endothelial Corneal Dystrophy (FECD) 2023-06-08
Overactive Bladder Treatment with Xeomin and Vibe Delivery System (XAVIER) Ended

2022-501759-95-00 Overactive bladder (OAB) 2023-06-05
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Metastatic Colorectal Cancer (mCRC) 2023-06-02
Plethysmography with acetylcholin and carbacholin – A clinical method study Ended

2023-503908-87-00 Vascular dysfunction 2023-06-02
Efficacy and tolerability of horse chestnut seed extract on swelling in patients undergoing meniscus surgery: a placebo-controlled, randomiz… Ended

2022-501154-11-00 post-operative swelling, pain and edema 2023-05-31
A study to investigate improvement in physical function in SF-36 with Vericiguat compared with Placebo in participants with post-COVID-19 sy… Ended

2024-517713-33-00 Post-COVID-19 syndrome without (PCS) or with (PCS/CFS) 2023-05-31
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENT… Ended

2023-510446-24-00 Cancer cachexia 2023-05-30